Overview

A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

Status:
Recruiting

Trial end date:
2026-10-01

Target enrollment:

Participant gender:

Summary

The main purpose of this study is to evaluate the safety and efficacy of tirzepatide in adolescents that have obesity or overweight with at least one weight-related comorbidity. The study will last approximately 90 weeks and may include up to 25 visits.

Phase:

Phase 3

Details

Lead Sponsor:

Eli Lilly and Company

Treatments:

Tirzepatide